Mouly SJ, Paine MF, Watkins PB. Contributions of CYP3A4, P-glycoprotein, and
serum protein binding to the intestinal first-pass extraction of saquinavir. J
Pharmacol Exp Ther 2004;308:941–948.
Mousa O, Brater DC, Sunblad KJ, Hall SD. The interaction of diltiazem with
simvastatin. Clin Pharmacol Ther 2000;67:267–274.
Muck W, Mai I, Fritsche L, Ochmann K, Rohde G, Unger S, Johne A, Bauer S, Budde
K, Roots I, Neumayer HH, Kuhlmann J. Increase in cerivastatin systemic exposure
after single and multiple dosing in cyclosporine-treated kidney transplant recipients.
Clin Pharmacol Ther 1999;65:251–261.
Mulato AS, Ho ES, Cihlar T. Nonsteroidal anti-inflammatory drugs efficiently reduce
the transport and cytotoxicity of adefovir mediated by the human renal organic
anion transporter 1. J Pharmacol Exp Ther 2000;295:10–15.
Muller M, Jansen PLM. Molecular aspects of hepatobiliary transport. Am J Physiol
1997;272:G1285–G1303.
Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very
susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol
Ther (St. Louis) 1998;63:332–341.
Neville K, Parise RA, Thompson P, Aleksic A, Egorin MJ, Balis FM, McGuffey L,
McCully C, Berg SL, Blaney SM. Plasma and Cerebrospinal Fluid Pharmacokinetics
of Imatinib after Administration to Nonhuman Primates. Clin Cancer Res
2004;10:25257–2529.
Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivisto KT. Effects of rifampin on
the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin
Pharmacol Ther (St. Louis, MO, United States) 2001;69:400–406.
Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT,
Kerb R, Schwab M, Neuvonen PJ, Eichelbaum M, Kivisto KT. High plasma
pravastatin concentrations are associated with single nucleotide polymorphisms and
haplotypes of organic anion transporting polypeptide-C (OATP-C. SLCO1B1).
Pharmacogenetics 2004;14:429–440.
Niemi M, Kivisto KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF.
Fexofenadine pharmacokinetics are associated with a polymorphism of the
SLCO1B1 gene (encoding OATP1B1). Br J Clin Pharmacol 2005;59:602–604.
Niemi M, Kivisto KT, Diczfalusy U, Bodin K, Bertilsson L, Fromm MF, Eichelbaum
M. Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin.
Pharmacogenet Genomics 2006a;16:565–568.
Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the
pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther
2006b;80:356–366.
Ninomiya M, Ito K, Horie T. Functional analysis of dog multidrug resistance-
associated protein 2 (MRP2) in comparison with rat MRP2. Drug Metab Dispos
2005;33:225–232.
Ocheltree SM, Shen H, Hu Y, Keep RF, Smith DE. Role and relevance of peptide trans-
porter 2 (PEPT2) in the kidney and choroid plexus:in vivostudies with glycylsarcosine
in wild type and PEPT2 knockout mice. J Pharm Exp Ther 2005;315:240–247.
Oerlemans R, van der Heijden J, Vink J, Dijkmans BAC, Kaspers GJL, Lems WF,
Scheffer GL, Ifergan I, Scheper RJ, Cloos J, Assaraf YG, Jansen G. Acquired
REFERENCES 195